

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop⦠read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
$54.62
Price-4.88%
-$2.80
$6.545b
Mid
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-25.0%
5y CAGR-$408.591m
-8.1%
1y CAGR-36.7%
3y CAGR-33.3%
5y CAGR-$3.31
-0.6%
1y CAGR-19.3%
3y CAGR-12.0%
5y CAGR$253.784m
$523.543m
Assets$269.759m
Liabilities$203.833m
Debt38.9%
-0.5x
Debt to EBITDA-$296.347m
+1.4%
1y CAGR-28.8%
3y CAGR-23.8%
5y CAGR